I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Idelalisib addition has neutral to beneficial effects on qu..:
Montillo, Marco
;
Illés, Árpad
;
Robak, Tadeusz
...
10.1186/s12955-019-1232-8. , 2023
Link:
https://hdl.handle.net/20.500.12210/82557
RT Journal T1
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial
UL https://suche.suub.uni-bremen.de/peid=base-ftunivlilleoa:oai:lilloa.univ-lille.fr:20.500.12210_82557&Exemplar=1&LAN=DE A1 Montillo, Marco A1 Illés, Árpad A1 Robak, Tadeusz A1 Pristupa, Alexander S A1 Wach, Malgorzata A1 Egyed, Miklós A1 Delgado, Julio A1 Jurczak, Wojciech A1 Morschhauser, Franck A1 Schuh, Anna A1 Eradat, Herbert A1 Shreay, Sanatan A1 Barrientos, Jacqueline C A1 Zelenetz, Andrew D PB BioMed Central YR 2023 K1 Randomized phase 3 study;Health-related quality of life;Patient-related outcomes;refractory CLL;Relapsed;Idelalisib JF 10.1186/s12955-019-1232-8 LK http://dx.doi.org/https://hdl.handle.net/20.500.12210/82557 DO https://hdl.handle.net/20.500.12210/82557 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)